Complete financial analysis of Sensus Healthcare, Inc. (SRTS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sensus Healthcare, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Changjiang & Jinggong Steel Building (Group) Co., Ltd (600496.SS) Income Statement Analysis – Financial Results
- Judges Scientific plc (JDG.L) Income Statement Analysis – Financial Results
- Exro Technologies Inc. (1O2.F) Income Statement Analysis – Financial Results
- Shanghai Haoyuan Chemexpress Co., Ltd. (688131.SS) Income Statement Analysis – Financial Results
- The Shibusawa Warehouse Co., Ltd. (9304.T) Income Statement Analysis – Financial Results
Sensus Healthcare, Inc. (SRTS)
About Sensus Healthcare, Inc.
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.41M | 44.53M | 27.04M | 9.58M | 27.26M | 26.43M | 20.59M | 14.81M | 10.27M | 5.81M | 10.48M |
| Cost of Revenue | 10.35M | 14.90M | 10.05M | 4.33M | 9.71M | 9.52M | 6.79M | 4.97M | 3.70M | 2.05M | 3.60M |
| Gross Profit | 14.06M | 29.63M | 16.99M | 5.25M | 17.56M | 16.91M | 13.80M | 9.85M | 6.57M | 3.76M | 6.88M |
| Gross Profit Ratio | 57.61% | 66.53% | 62.82% | 54.81% | 64.40% | 63.99% | 67.03% | 66.48% | 64.00% | 64.63% | 65.64% |
| Research & Development | 3.68M | 3.46M | 3.44M | 4.16M | 6.42M | 6.26M | 5.49M | 1.82M | 1.47M | 1.58M | 1.33M |
| General & Administrative | 5.16M | 5.01M | 4.59M | 3.99M | 4.00M | 4.12M | 3.72M | 3.47M | 1.59M | 1.65M | 1.45M |
| Selling & Marketing | 5.61M | 6.33M | 4.84M | 5.34M | 9.10M | 8.53M | 8.31M | 4.92M | 3.74M | 4.21M | 3.97M |
| SG&A | 10.76M | 11.34M | 9.43M | 9.33M | 13.11M | 12.66M | 12.03M | 8.38M | 5.33M | 5.86M | 5.42M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.44M | 14.80M | 12.87M | 13.48M | 19.53M | 18.92M | 17.52M | 10.21M | 6.80M | 7.44M | 6.75M |
| Cost & Expenses | 24.79M | 29.70M | 22.92M | 17.81M | 29.23M | 28.43M | 24.31M | 15.17M | 10.49M | 9.49M | 10.35M |
| Interest Income | 992.00K | 382.00K | 2.00K | 52.56K | 268.29K | 139.28K | 75.81K | 38.54K | 1.78K | 820.00 | 1.25K |
| Interest Expense | 0.00 | 2.00K | 1.00K | 14.23K | 0.00 | 156.69K | 68.88K | 21.87K | 17.79K | 20.03K | 20.47K |
| Depreciation & Amortization | 461.00K | 315.00K | 613.00K | 721.87K | 545.72K | 658.26K | 387.92K | 337.58K | 315.60K | 272.65K | 265.56K |
| EBITDA | 79.00K | 14.83M | 4.73M | -6.10M | -1.15M | -1.21M | -3.25M | 13.00K | 96.12K | -3.41M | 393.65K |
| EBITDA Ratio | 0.32% | 34.16% | 15.24% | -100.03% | -6.24% | -7.06% | -17.69% | -2.19% | 0.94% | -58.63% | 3.76% |
| Operating Income | -382.00K | 14.83M | 4.12M | -8.23M | -1.97M | -2.01M | -3.72M | -363.12K | -221.26K | -3.68M | 126.84K |
| Operating Income Ratio | -1.57% | 33.30% | 15.24% | -85.98% | -7.22% | -7.59% | -18.06% | -2.45% | -2.15% | -63.34% | 1.21% |
| Total Other Income/Expenses | 1.03M | 13.16M | -1.00K | 1.40M | 268.29K | -17.41K | 6.93K | 16.67K | -16.01K | -19.21K | -19.21K |
| Income Before Tax | 652.00K | 27.99M | 4.12M | -6.84M | -1.70M | -2.02M | -3.71M | -346.45K | -237.27K | -3.70M | 107.63K |
| Income Before Tax Ratio | 2.67% | 62.85% | 15.23% | -71.37% | -6.24% | -7.65% | -18.02% | -2.34% | -2.31% | -63.67% | 1.03% |
| Income Tax Expense | 167.00K | 3.75M | -613.00K | -2.12M | -545.72K | 139.28K | -312.11K | -299.05K | 1.78K | 820.00 | 1.25K |
| Net Income | 485.00K | 24.24M | 4.12M | -4.72M | -1.15M | -2.02M | -3.71M | -346.45K | -237.27K | -3.70M | 107.63K |
| Net Income Ratio | 1.99% | 54.44% | 15.23% | -49.24% | -4.23% | -7.65% | -18.02% | -2.34% | -2.31% | -63.67% | 1.03% |
| EPS | 0.03 | 1.47 | 0.25 | -0.29 | -0.07 | -0.14 | -0.28 | -0.03 | -0.02 | -0.37 | -0.04 |
| EPS Diluted | 0.03 | 1.46 | 0.25 | -0.29 | -0.07 | -0.14 | -0.28 | -0.03 | -0.02 | -0.37 | -0.04 |
| Weighted Avg Shares Out | 16.26M | 16.48M | 16.48M | 16.43M | 16.23M | 14.12M | 13.24M | 12.03M | 10.78M | 9.88M | 9.79M |
| Weighted Avg Shares Out (Dil) | 16.27M | 16.62M | 16.50M | 16.43M | 16.23M | 14.12M | 13.24M | 12.03M | 10.78M | 9.89M | 9.89M |
Wall Street Bulls Look Optimistic About Sensus Healthcare (SRTS): Should You Buy?
Wall Street Analysts Believe Sensus Healthcare (SRTS) Could Rally 36.01%: Here's is How to Trade
Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?
Pompano Veterinary Oncology Partners with Sensus Healthcare to Provide First Superficial Radiotherapy Services in a Mobile Configuration
Wall Street Analysts See a 39.66% Upside in Sensus Healthcare (SRTS): Can the Stock Really Move This High?
What Makes Sensus Healthcare (SRTS) a Good Fit for 'Trend Investing'
REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
Sensus Healthcare: Q3 Results Showed That The Stock Is Undervalued
Sensus Healthcare, Inc. (SRTS) Q3 2024 Earnings Call Transcript
Sensus Healthcare, Inc. (SRTS) Surpasses Q3 Earnings and Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports